Lifecore Biomedical reports transition period revenue $75.5M (+20% y/y), Adj. EBITDA $13.1M

LIFECORE BIOMEDICAL, INC. DE

Revenue for seven-month transition period $75.5M, +20% vs prior comparable period; Q4 revenue $35.7M, +10% y/y.
Net loss for transition period $18.0M, improved from $30.6M; Adjusted EBITDA $13.1M, up from $2.6M.
Gross margin 31% vs 26%; operating expenses decreased 31% to $24.4M.
Signed five new programs during transition, including two commercial site transfer programs in Q4.
Liquidity of $38.9M at quarter end; mid-term target: 12% revenue CAGR, EBITDA margins >25%.

item 2.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001005286-26-000007
form_type: 8-K
ticker: LFCR
cik: 0001005286
company_name: LIFECORE BIOMEDICAL, INC. DE
filed_at: 2026-03-16T23:59:59+00:00
discovered_at: 2026-05-14T18:02:34.386605+00:00
generated_at: 2026-05-15T11:18:46.905643+00:00
sec_items: ["2.02", "7.01", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001005286-26-000007
json_url: https://secwatch.observer/filing/0001005286-26-000007.json
markdown_url: https://secwatch.observer/filing/0001005286-26-000007.md
text_url: https://secwatch.observer/filing/0001005286-26-000007.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000007/0001005286-26-000007-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000007/lndc-20260316.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001005286-26-000007

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.